Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14654)	9/16/2000 9:16:14 PM
From: Robert K.	Read Replies (3) \| Respond to of 17367

So Cacaito, are you saying that doing a trial in africa as you suggest would make qualifing data for approval IN the USA and Europe? Please, you are smarter then to throw around that manure. Regarding endotoxins, agree with you 100%, not proven culprits, but infered by maybe 98% in the field. Regarding clots, bpi does disolove clots and prevent clots. You are wrong.

To: Cacaito who wrote (14654)	9/16/2000 9:16:26 PM
From: Bluegreen	Respond to of 17367

You stated>>>>>>>>Bax could commit itself for the kids, and xoma, and with good $100 to $200 they could do a very good trial in Africa, plenty of subjects, not even need for individual informed consent, institutional one is accepted in Africa, immediate oral consent as minimal requirement pre or post use is possible. And this is FACT.<<<<< What are you talking about???